






Letters to the Editor: Published Article

Reported Case Report of Recovery From Rabies Using Intrathecal Rabies Immune Globulin was Flawed

Alan C. Jackson¹ , Charles E. Rupprecht² , Reeta S. Mani³ , Nidia Aréchiga-Ceballos⁴  and Darryn L. Knobel⁵ 

¹Department of Clinical Neurosciences, University of Calgary Cumming School of Medicine, Calgary, AB, Canada, ²Auburn University, Auburn, AL, USA, ³National Institute of Mental Health and Neurosciences, Bangalore, India, ⁴Instituto de Diagnostico y Referencia Epidemiologicos, Direccion General de Epidemiologia, Secretaria de Salud, Ciudad de Mexico, Mexico and ⁵Ross University School of Veterinary Medicine, St. Kitts and Nevis, West Indies

Keywords: Encephalitis; intrathecal injections; myelitis; polymerase chain reaction; rabies; rabies immune globulin

We have read the recent report in BMJ Case Reports by Ing et al. that claims an adolescent girl developed rabies in Malaysia and had a complete recovery after successful treatment with four doses of intrathecal rabies immune globulin (RIG).¹ We are very concerned about numerous flaws in this report and recommend that it be disregarded when treatment options are considered for future patients with rabies.

Insufficient details are presented about the case and the post-exposure rabies prophylaxis to determine the extent of compliance with World Health Organization recommendations. The suspect dog was not available for diagnostic testing. Three doses of an unknown rabies vaccine were administered to the patient. It is unknown whether all wounds were infiltrated thoroughly with RIG (the report states “She received . . . a dose of RIG . . .”).

The symptoms of numbness, pain, and paraesthesias suggest the possibility of prodromal symptoms due to infection and inflammation in local dorsal root ganglia.² However, the documented sensory loss is a non-anatomical distribution (distal to the elbow) that is not helpful.

No symptoms or signs are reported suggesting clinical evidence of rabies encephalitis or myelitis, which would be expected to develop within a very short time after neurological prodromal symptoms. The first dose of intrathecal RIG was not given until the 4th hospital day and no clinical features of rabies encephalitis or myelitis were reported during this interval, which would be unusual if this was actually a case of rabies.

In order to have positive polymerase chain reaction (PCR) results for detection of rabies virus RNA, there must be centrifugal spread of the infection from the central nervous system to extraneural organs. Detection of rabies virus RNA in urine is not a sensitive diagnostic test for rabies. Saliva is a much more reliable fluid sample for detection of rabies virus RNA by a PCR assay.³ In this report, saliva was negative on samples from 11 different days. Detection was positive only on day 1 in urine, but not in saliva or cerebrospinal fluid (CSF), at a time in which there were no clinical features of rabies encephalomyelitis, which raises serious concerns about potential problems with the PCR assay. Similarly, a positive assay in CSF only on day 6 is questionable. The PCR method was not presented or referenced

and values for quantitative PCR were not given. PCR products should be sequenced to confirm the identity of the rabies virus variant, which was also not reported.

Patients that have rabies encephalomyelitis develop neutralizing anti-rabies virus antibodies in the CSF and patients that recover from rabies (or are successfully immunized) develop antibodies in their sera. No serology results were presented on sera or CSF. A skin biopsy was also not performed for detection of rabies virus antigen and/or RNA.

Administration of RIG by repeated lumbar intrathecal injections does not ensure good delivery to presumed infected CNS neurons. There is a good chance of development of a CSF leak, particularly with repeated injections, resulting in poor delivery to the intended targets. Theoretically intraventricular administration would be more favorable.

In summary, there is considerable uncertainty about whether the reported case actually had rabies because of the clinical features and laboratory evaluation. The delivery of intrathecal RIG via lumbar injections is questionable. We are also aware of unsuccessful attempts at therapy reported with both intravenous⁴ and intrathecal infusion⁵ of RIG in rabies patients. Hence, this report should not be considered a successful therapeutic outcome and we recommend that physicians should only embark on a similar approach with great caution and keeping our serious reservations in mind.

Funding. None.

Competing interests. Alan C. Jackson has received royalties from Elsevier Academic Press, MedLink Neurology, and UpToDate and an honorarium from Cadila Pharmaceuticals (India). Charles E. Rupprecht has received royalties from Springer and Merck, he has a leadership role with Rabies in the Americas, Inc., and he has received consulting fees, honoraria, and travel support for attending meetings from Lyssa LLC. Reeta S. Mani has provided laboratory services in support of rabies vaccine clinical trials conducted by Cadila Pharmaceuticals (India) and the Serum Institute of India. She has received an honorarium from the Association for Prevention and Control of Rabies in India. Nidia Aréchiga-Ceballos has a leadership role in Kanan. Darryn L. Knobel has a leadership role in the Canine Rabies Treatment Initiative.

Statement of authorship. ACJ, CER, RSM, NAC, and DLK each contributed to the writing of this manuscript.

Corresponding author: A. C. Jackson; Email: alan.jackson@ucalgary.ca

Cite this article: Jackson AC, Rupprecht CE, Mani RS, Aréchiga-Ceballos N, and Knobel DL. Reported Case Report of Recovery From Rabies Using Intrathecal Rabies Immune Globulin was Flawed. *The Canadian Journal of Neurological Sciences*, <https://doi.org/10.1017/cjn.2023.319>

References

1. Ing SK, Ng Han SB, Lee YH, Ling TY. Case of human rabies despite post-exposure prophylaxis (PEP) and complete recovery after intrathecal rabies immunoglobulin (RIG). *BMJ Case Rep.* 2023;16:e256408.
2. Jackson AC. Human disease. In: Fooks AR, Jackson AC, editors. *Rabies: scientific basis of the disease and its management*, 4th ed. London: Elsevier Academic Press; 2020, pp. 277–302.
3. McElhinney LM, Marston DA, Golding M, Nadin-Davis SA. Laboratory diagnosis of rabies. In: Fooks AR, Jackson AC, editors. *Rabies: scientific basis of the disease and its management*, 4th ed. London: Elsevier Academic Press; 2020, pp. 401–44.
4. Hemachudha T, Sunsaneewitayakul B, Mitrabhakdi E, et al. Paralytic complications following intravenous rabies immune globulin treatment in a patient with furious rabies (Letter). *Int J Infect Dis.* 2003; 7:76–7.
5. Lee M, Carlo-Anglero A, Runyon J, Burks D, Scully P, Dahm P. Intrathecal rabies immune globulin: salvage therapy for rabies encephalitis for a pediatric patient (Abstract). *Crit Care Med.* 2023;51:200–200.